| (a) The PEFC maintains and updates the HHSC Psychiatric
Drug Formulary by:
(1) recommending standards of drug use that discourage
unnecessary duplication of therapeutic alternatives and encourage
the highest standards of medical and pharmacy practice;
(2) periodically reviewing the drugs listed in the
formulary to ensure consistency with need, effectiveness, risk, and
cost;
(3) consulting with experts in clinical pharmacy, pharmacology,
and other medical specialties as necessary to objectively assess drugs
under consideration; and
(4) considering the applications submitted in accordance
with §306.357 of this subchapter (relating to Adding a Drug to
the HHSC Psychiatric Drug Formulary) or as:
(A) presented by committee members; or
(B) submitted by other qualified persons at the invitation
of the PEFC chairperson.
(b) The PEFC may make other recommendations concerning
drug use and policy.
(c) Approval of a drug entity for inclusion in the
HHSC Psychiatric Drug Formulary does not imply approval of all formulations
for that drug. The PEFC designates the formulations that are allowed
for general use by service system components and their contractors.
(d) Approval of a drug formulation constitutes approval
of all brands of the product that have been proven to be bioequivalent
as listed in the then-current Approved Drug Products with Therapeutic
Equivalence Evaluations, published by the United States Food and Drug
Administration.
(e) For a drug entity that has known bioequivalency
problems, the PEFC may limit its use to a specific brand based on
objective clinical pharmacokinetic data.
|
